DXCM vs. MDT, BDX, EW, IDXX, RMD, STE, PODD, BAX, HOLX, and MASI
Should you be buying DexCom stock or one of its competitors? The main competitors of DexCom include Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), STERIS (STE), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), and Masimo (MASI). These companies are all part of the "health care equipment" industry.
DexCom vs.
DexCom (NASDAQ:DXCM) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings.
Medtronic received 603 more outperform votes than DexCom when rated by MarketBeat users. Likewise, 75.33% of users gave Medtronic an outperform vote while only 71.85% of users gave DexCom an outperform vote.
DexCom has a net margin of 14.29% compared to Medtronic's net margin of 12.83%. DexCom's return on equity of 30.14% beat Medtronic's return on equity.
DexCom presently has a consensus price target of $98.32, suggesting a potential upside of 15.86%. Medtronic has a consensus price target of $97.00, suggesting a potential upside of 9.63%. Given DexCom's stronger consensus rating and higher possible upside, equities research analysts plainly believe DexCom is more favorable than Medtronic.
97.8% of DexCom shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 0.2% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Medtronic had 21 more articles in the media than DexCom. MarketBeat recorded 34 mentions for Medtronic and 13 mentions for DexCom. DexCom's average media sentiment score of 1.27 beat Medtronic's score of 1.19 indicating that DexCom is being referred to more favorably in the media.
DexCom has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.
Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Summary
DexCom beats Medtronic on 13 of the 19 factors compared between the two stocks.
Get DexCom News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:DXCM) was last updated on 6/10/2025 by MarketBeat.com Staff
